ArticleCancer research communications2022

Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma.

Kateryna Krytska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.